KR20210021946A - 인간 제대 조직 유래 중간엽 간질 세포를 사용한 뇌성마비 및 저산소-허혈성 뇌병증 치료 방법 - Google Patents

인간 제대 조직 유래 중간엽 간질 세포를 사용한 뇌성마비 및 저산소-허혈성 뇌병증 치료 방법 Download PDF

Info

Publication number
KR20210021946A
KR20210021946A KR1020207031726A KR20207031726A KR20210021946A KR 20210021946 A KR20210021946 A KR 20210021946A KR 1020207031726 A KR1020207031726 A KR 1020207031726A KR 20207031726 A KR20207031726 A KR 20207031726A KR 20210021946 A KR20210021946 A KR 20210021946A
Authority
KR
South Korea
Prior art keywords
hct
msc
study
patient
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207031726A
Other languages
English (en)
Korean (ko)
Inventor
조안느 커츠버그
제시카 선
알렌 송
찰스 마이클 코튼
Original Assignee
듀크 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 듀크 유니버시티 filed Critical 듀크 유니버시티
Publication of KR20210021946A publication Critical patent/KR20210021946A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207031726A 2018-04-04 2019-04-04 인간 제대 조직 유래 중간엽 간질 세포를 사용한 뇌성마비 및 저산소-허혈성 뇌병증 치료 방법 Ceased KR20210021946A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652818P 2018-04-04 2018-04-04
US62/652,818 2018-04-04
PCT/US2019/025796 WO2019195554A1 (en) 2018-04-04 2019-04-04 Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells

Publications (1)

Publication Number Publication Date
KR20210021946A true KR20210021946A (ko) 2021-03-02

Family

ID=68101217

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207031726A Ceased KR20210021946A (ko) 2018-04-04 2019-04-04 인간 제대 조직 유래 중간엽 간질 세포를 사용한 뇌성마비 및 저산소-허혈성 뇌병증 치료 방법

Country Status (11)

Country Link
US (1) US20210361716A1 (https=)
EP (1) EP3773624A4 (https=)
JP (1) JP2021520353A (https=)
KR (1) KR20210021946A (https=)
CN (1) CN112236152A (https=)
AU (1) AU2019247383B2 (https=)
BR (1) BR112020020288A2 (https=)
CA (1) CA3096037A1 (https=)
IL (1) IL277732A (https=)
SG (1) SG11202009800SA (https=)
WO (1) WO2019195554A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024075676A1 (ja) * 2022-10-03 2024-04-11 キッズウェル・バイオ株式会社 脳性まひの予防又は治療剤
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1803193A (zh) * 2005-01-13 2006-07-19 中山大学 骨髓来源的间质干细胞用于制备治疗缺氧缺血性脑性瘫痪的制剂的用途
US20070128722A1 (en) * 2005-12-05 2007-06-07 Industrial Technology Research Institute Human mesenchymal stem cells and culturing methods thereof
US20170042944A1 (en) * 2014-04-21 2017-02-16 Anthrogenesis Corporation Treatment of conditions and complications in infants
WO2016019332A1 (en) * 2014-07-29 2016-02-04 Ingeneron, Inc. Method and apparatus for recovery of umbilical cord tissue derived regenerative cells and uses thereof
WO2017144552A1 (en) * 2016-02-22 2017-08-31 Centauri Biotech. S.L. Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso)
JP7126703B2 (ja) * 2016-05-24 2022-08-29 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
KR101973284B1 (ko) * 2017-01-16 2019-04-29 사회복지법인 삼성생명공익재단 신생아 ｈｉｅ 치료용 조성물

Also Published As

Publication number Publication date
AU2019247383B2 (en) 2025-11-27
EP3773624A4 (en) 2022-01-12
WO2019195554A1 (en) 2019-10-10
AU2019247383A1 (en) 2020-10-29
EP3773624A1 (en) 2021-02-17
BR112020020288A2 (pt) 2021-01-12
SG11202009800SA (en) 2020-11-27
IL277732A (en) 2020-11-30
US20210361716A1 (en) 2021-11-25
CA3096037A1 (en) 2019-10-10
CN112236152A (zh) 2021-01-15
JP2021520353A (ja) 2021-08-19

Similar Documents

Publication Publication Date Title
Ohlsson et al. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants
Ohlsson et al. Early erythropoiesis‐stimulating agents in preterm or low birth weight infants
Bruschettini et al. Stem cell‐based interventions for the prevention of morbidity and mortality following hypoxic‐ischaemic encephalopathy in newborn infants
Sagar et al. Fetal stem cell transplantation and gene therapy
Zhou et al. Feasibility and safety of autologous cord blood derived cell administration in extremely preterm infants: a single-centre, open-label, single-arm, phase I trial (CORD-SaFe study)
Hoang et al. Allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (COPD): study protocol for a matched case–control, phase I/II trial
Zhou et al. Feasibility of cord blood collection for autologous cell therapy applications in extremely preterm infants
KR20210021946A (ko) 인간 제대 조직 유래 중간엽 간질 세포를 사용한 뇌성마비 및 저산소-허혈성 뇌병증 치료 방법
Stark et al. Study protocol of the WashT Trial: transfusion with washed versus unwashed red blood cells to reduce morbidity and mortality in infants born less than 28 weeks’ gestation-a multicentre, blinded, parallel group, randomised controlled trial
EP3773486B1 (en) Umbilical cord tissue-derived mesenchymal stromal cells for use in the treatment of autism spectrum disorders
Zhou et al. Early neurodevelopment of extremely preterm infants administered autologous cord blood cell therapy: secondary analysis of a nonrandomized clinical trial
HK40044465A (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
US20200016213A1 (en) Methods of Treating Cerebral Palsy Using High Dose Allogeneic Umbilical Cord Blood
Diao et al. Clinical trial of intrathecal injection of protein polymers for apoplexy: A protocol
US20250312383A1 (en) Human umbilical cord blood for use in alleviating fatigue
Thwala The quality of neonatal inter-facility transport systems within the Johannesburg metropolitan region
MacKenzie et al. In Utero Hematopoietic Cell Transplantation in Fetuses with Alpha Thalassemia Major: A Phase 1 Clinical Trial
Waddell et al. Anaesthesia for patients with sickle cell and other haemoglobinopathies
David et al. An exploratory phase I/II trial evaluating the safety and efficacy of postnatal or pre-and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta: The BOOSTB4 Trial Protocol
Zhuxiao et al. Autologous cord blood mononuclear cell infusion for the prevention of bronchopulmonary dysplasia in very preterm monozygotic twins: A study protocol for a randomized, placebo-controlled, double-blinded multicenter trial
Osunkwo Sickle Cell Disease–More than just a painful disorder
TIGENIX CLINICAL STUDY PROTOCOL
Mkrtchyan et al. THE PROBLEM OF ANEMIA IN ARMENIA AMONG YOUNG CHILDREN
Morris et al. Anemia in the Nursery: When to Observe, When to Treat, and When to Refer
Arts et al. Methylphenidate, a companion in young age and a foe in old age?

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201103

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220401

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250205

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250409

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D